PL2089364T3 - Związki pirydynonu - Google Patents

Związki pirydynonu

Info

Publication number
PL2089364T3
PL2089364T3 PL07844974T PL07844974T PL2089364T3 PL 2089364 T3 PL2089364 T3 PL 2089364T3 PL 07844974 T PL07844974 T PL 07844974T PL 07844974 T PL07844974 T PL 07844974T PL 2089364 T3 PL2089364 T3 PL 2089364T3
Authority
PL
Poland
Prior art keywords
pyridinone compounds
pyridinone
compounds
Prior art date
Application number
PL07844974T
Other languages
English (en)
Inventor
Robert M Borzilleri
Gretchen M Schroeder
Zhen-Wei Cai
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PL2089364T3 publication Critical patent/PL2089364T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
PL07844974T 2006-11-08 2007-11-08 Związki pirydynonu PL2089364T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85754006P 2006-11-08 2006-11-08
EP07844974.1A EP2089364B1 (en) 2006-11-08 2007-11-08 Pyridinone compounds
PCT/US2007/084047 WO2008058229A1 (en) 2006-11-08 2007-11-08 Pyridinone compounds

Publications (1)

Publication Number Publication Date
PL2089364T3 true PL2089364T3 (pl) 2013-11-29

Family

ID=39048786

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07844974T PL2089364T3 (pl) 2006-11-08 2007-11-08 Związki pirydynonu

Country Status (20)

Country Link
US (2) US7851489B2 (pl)
EP (1) EP2089364B1 (pl)
JP (1) JP5276005B2 (pl)
KR (1) KR101390076B1 (pl)
CN (1) CN101535264B (pl)
AR (1) AR063628A1 (pl)
AU (1) AU2007317296B2 (pl)
CA (1) CA2669266C (pl)
CL (1) CL2007003226A1 (pl)
DK (1) DK2089364T3 (pl)
ES (1) ES2424851T3 (pl)
HR (1) HRP20130626T1 (pl)
MX (1) MX2009004699A (pl)
NO (1) NO342395B1 (pl)
PE (1) PE20081490A1 (pl)
PL (1) PL2089364T3 (pl)
PT (1) PT2089364E (pl)
SI (1) SI2089364T1 (pl)
TW (1) TWI409259B (pl)
WO (1) WO2008058229A1 (pl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5693239B2 (ja) * 2008-01-23 2015-04-01 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 4−ピリジノン化合物および癌についてのその使用
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
CA2800998A1 (en) 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
SG184891A1 (en) 2010-04-30 2012-11-29 Bristol Myers Squibb Co Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide
CN102241625B (zh) * 2010-05-13 2014-10-29 中南大学 1-(取代芳基)-5-((取代芳胺基)甲基)吡啶-2(1h)酮化合物、制备方法及其用途
CN102070518B (zh) * 2011-01-24 2012-05-02 江苏先声药物研究有限公司 取代吡啶及氮杂吲哚衍生物的合成
MX354412B (es) 2011-06-10 2018-03-05 Merck Patent Gmbh Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
JP2015507606A (ja) * 2011-11-22 2015-03-12 デシフェラ ファーマシューティカルズ,エルエルシー 抗癌および抗増殖作用を示すピリドンアミドおよび類似体
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
JP6342392B2 (ja) 2012-07-28 2018-06-13 カリター・サイエンシーズ・エルエルシー 置換型ピラゾロン化合物及び使用方法
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
EP3484866B1 (en) * 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US10633341B2 (en) * 2016-12-19 2020-04-28 Novartis Ag Picolinic acid derivatives and their use as intermediates
JP7101678B2 (ja) 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
TW201834649A (zh) 2017-03-02 2018-10-01 新加坡商亞獅康私人有限公司 癌症療法
CN108623568B (zh) * 2017-03-21 2022-04-19 南京汇诚制药有限公司 9,10二氢菲类丙型肝炎病毒抑制剂的盐型及其制备
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2019083455A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS PRESENTING HER1, HER2 AND / OR HER3-ACTIVATED HERC-RECEPTOR CANCER CELLS
WO2019083456A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER FOR NORMALIZING ANGIOGENESIS IN A CANCER MASS
WO2019083458A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR THE TREATMENT OF CANCER TO REDUCE HYPOXIA
WO2019083457A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS MUTATION OF THE BETA-CATENIN PATHWAY
US11623923B2 (en) * 2017-11-24 2023-04-11 Medshine Discovery, Inc. Uracil compound as c-MET/AXL inhibitor
WO2019182274A1 (en) 2018-03-08 2019-09-26 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
SMT202500157T1 (it) 2018-03-30 2025-05-12 Incyte Corp Composti eterociclici come immunomodulatori
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
JP2022504201A (ja) 2018-10-09 2022-01-13 アスラン ファーマシューティカルズ ピーティーイー リミテッド バリチニブのマロン酸塩
JP2022505272A (ja) * 2018-10-19 2022-01-14 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア がん治療のためのトポイソメラーゼii触媒阻害剤化合物による治療、方法、及び使用
US12595273B2 (en) 2019-01-15 2026-04-07 The Translational Genomics Research Institute Phosphonate conjugates and uses thereof
US20220235064A1 (en) * 2019-08-02 2022-07-28 Wellmarker Bio Co., Ltd. Oxo-pyridine fusion ring derivative and pharmaceutical composition comprising same
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Pd-1/pd-l1阻害剤の塩
EP3819300A4 (en) 2019-09-06 2021-11-24 Wellmarker Bio Co., Ltd. THERAPEUTIC COMPOSITION BASED ON BIOMARKERS
PE20221038A1 (es) 2019-09-30 2022-06-17 Incyte Corp Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores
CA3160131A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
JP2023513675A (ja) 2020-02-06 2023-04-03 ウェルマーカー・バイオ・カンパニー・リミテッド Kras変異に関連する癌の予防または治療のための医薬組成物
KR20210111711A (ko) 2020-03-03 2021-09-13 웰마커바이오 주식회사 Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물
US20230202992A1 (en) 2020-05-18 2023-06-29 Wellmarker Bio Co., Ltd. Pharmaceutical composition for preventing or treating small-cell lung cancer associated with ron mutants and method using same
KR20210142555A (ko) 2020-05-18 2021-11-25 웰마커바이오 주식회사 Ron 돌연변이와 관련된 췌장암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법
JP2023526443A (ja) 2020-05-18 2023-06-21 ウェルマーカー バイオ カンパニー リミテッド Ron変異が関与する非小細胞肺がんの予防又は治療用医薬組成物及びその使用方法
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Pd—1/pd—l1抑制劑之結晶形式
CR20230230A (es) 2020-11-06 2023-07-27 Incyte Corp Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
WO2022169248A1 (ko) * 2021-02-02 2022-08-11 주식회사 엘지화학 단백질 키나아제 억제제로서의 신규한 화합물
KR20220170766A (ko) * 2021-06-22 2022-12-30 주식회사 엘지화학 단백질 키나아제 억제제로서의 신규한 화합물
US20230257364A1 (en) * 2022-02-16 2023-08-17 Cmg Pharmaceutical Co., Ltd. Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof
KR20240101434A (ko) * 2022-12-23 2024-07-02 주식회사 엘지화학 Ron 억제제로서 신규한 화합물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430885A3 (en) 1989-12-01 1991-11-06 Ciba-Geigy Ag Anthelmintical compounds
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
CA2333554A1 (en) 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
ES2546386T3 (es) 1999-07-20 2015-09-23 Dow Agrosciences, Llc Amidas aromáticas heterocíclicas fungicidas y sus composiciones, métodos de uso y preparación
US6355660B1 (en) 1999-07-20 2002-03-12 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
CA2384291A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
SE0102384D0 (sv) 2001-07-03 2001-07-03 Pharmacia Ab New compounds
US20050038035A1 (en) 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
JP4829506B2 (ja) 2004-02-17 2011-12-07 石原産業株式会社 チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
CA2564355C (en) 2004-05-07 2012-07-03 Amgen Inc. Protein kinase modulators and method of use
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
SI2089364T1 (sl) 2013-10-30
NO342395B1 (no) 2018-05-14
PT2089364E (pt) 2013-08-26
JP2010509362A (ja) 2010-03-25
AR063628A1 (es) 2009-02-04
AU2007317296A1 (en) 2008-05-15
CA2669266C (en) 2014-04-29
CL2007003226A1 (es) 2008-02-08
HK1131608A1 (en) 2010-01-29
JP5276005B2 (ja) 2013-08-28
CN101535264B (zh) 2012-11-28
ES2424851T3 (es) 2013-10-09
EP2089364B1 (en) 2013-06-12
CA2669266A1 (en) 2008-05-15
DK2089364T3 (da) 2013-09-02
US8536200B2 (en) 2013-09-17
CN101535264A (zh) 2009-09-16
KR20090096423A (ko) 2009-09-10
PE20081490A1 (es) 2008-10-30
KR101390076B1 (ko) 2014-04-29
HRP20130626T1 (en) 2013-08-31
NO20091605L (no) 2009-05-27
EP2089364A1 (en) 2009-08-19
MX2009004699A (es) 2009-05-15
WO2008058229A1 (en) 2008-05-15
US7851489B2 (en) 2010-12-14
US20080114033A1 (en) 2008-05-15
US20110052583A1 (en) 2011-03-03
TW200829564A (en) 2008-07-16
TWI409259B (zh) 2013-09-21
AU2007317296B2 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
HRP20130626T1 (en) Pyridinone compounds
GB0608263D0 (en) Compounds
GB0602424D0 (en) Compounds
GB0602046D0 (en) Compounds
EP1984379A4 (en) ANTI-ARENAVIRAL COMPOUNDS
GB0605786D0 (en) Compounds
GB0606876D0 (en) Compounds
EP2082022A4 (en) COMPOUNDS
GB0607175D0 (en) Compounds
EP2004174A4 (en) NAPHTHALENEDIONED COMPOUNDS
GB0607398D0 (en) Compounds
GB0605784D0 (en) Compounds
GB0606913D0 (en) Compounds
GB0602042D0 (en) Compounds
AP2009004767A0 (en) Cubstituted azolin-2-yl-amino compounds
EP1973905A4 (en) COMPOUNDS
GB0600427D0 (en) Compounds
GB0607839D0 (en) Compounds
GB0603133D0 (en) Compounds
GB0602040D0 (en) Compounds
GB0607978D0 (en) Compounds
GB0605588D0 (en) Compounds
GB0605589D0 (en) Compounds
GB0607409D0 (en) Npvel compounds
GB0604377D0 (en) Compounds